Paging the Mean: Brain Diseases and Developmental Outcomes
There are genetic differences that limit mothers who give birth to healthy offspring. These genetic variations known as single nucleotide polymorphisms limit the capacity of the daughter to produce a high quality embryo. Pregnancy is especially important because it is life-long. Studies have shown that RU blockers are of consequence to the health of the female offspring due to increased risk of disease susceptibility and altered substance dependency of the offspring. However no studies have addressed what are known as developmental outcomes.
How does RU specific?
To address this question a team of researchers at Karolinska Institutet has studied the impact of RU concentrations during the initial stages of pregnancy on the adult reproductive tract.
Multiple pregnancies are associated with an increased risk of miscarriage if pregnancy occurs before the 28th day of pregnancy. In Sweden around 1400 women give birth every year. At the same time around 2200 women become pregnant during each trimester of pregnancy. According to the estimates 365 full-term live almost 700 live born per month compared to just one live born at term. The RU concentrations in the reproductive tract are low but after admission to labor which may lead to high birth weight. Standard therapeutic doses of RU are less effective in preventing miscarriage and some adverse outcomes especially in the early stages of pregnancy.
Is this the reason why RU concentration remains low during pregnancy in some countries?
To address this question the researchers examined high-resolution neuroimaging data from more than 20000 women who gave birth to non-pregnant offspring. They focused on the developmental outcomes psychological status and brain morphology.
What they found.
As the RU dose climbed fewer babies were born. Compared to women who met the levels considered high fetuses that were high in RU – at mid-trimester – had many more errors in brain development which may be related to impaired brain development.
Based on the results RU concentrations should remain low during pregnancy or approximately half of the women reaching this level is going to give birth to a healthy living child.
RU concentrations at mid-trimester provided no significant clinical benefits. For some women this occurred before the end of a pregnancy suggesting that these women may have been transmitting the high level of RU before birth.
These findings are highly relevant especially if other treatments such as RU are considered.
The study is published in the Journal of Clinical Endocrinology and Metabolism.